eumelanin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-30. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
In May 2023, Ajinomoto signed a letter of intent for a strategic alliance with Solar Foods, a company that developed Solein, a microbial protein feeding on CO2 as a nutrient source, and obtained a marketing license in Singapore. In November 2023, Ajinomoto acquired US-based Forge Biologics for $620 million. In September 2024, Ajinomoto entered into a global strategic partnership with Danone to reduce greenhouse gas emissions from Danone’s raw milk supply chain. In the same year, through joint research with Professor Chinatsu Kasamatsu (Project Professor) of the Institute for SDGs Promotion at Ochanomizu University in Japan, Ajinomoto became the first in the world to develop a new concept of 'electric seasoning,' which adjusts the taste of food using transdermal electrical stimulation. In March 2025, Ajinomoto decided to participate as a partner in the 'Demonstration Survey for the Restoration Model of Degraded Agricultural Land in Brazil,' a project under the Japan-Brazil Green Partnership Initiative promoted by the governments of Japan and Brazil. In April 2025, Ajinomoto was selected by CDP, an international environmental not-for-profit charity, for its "Climate Change A-List" for fiscal 2024. This is the fifth consecutive year that Ajinomoto has been selected for the A-list.
== History == Polymer Char was founded by B. Monrabal in 1992 in the Valencia Technology Park, in Spain, being registered with the name of Polymer Characterization, S.A. Its initial goal was to develop a commercial Crystallization Analysis Fractionation (CRYSTAF) instrument based on technology developed by Monrabal at Dow Chemical Company laboratories in the Netherlands to measure chemical composition distribution in semicrystalline polymers. A CRYSTAF prototype was presented at Pittcon in 1994. The first product was acquired in 1995 by a petrochemical company in South Korea. The company has also developed techniques and instruments for polymer characterization, and more specifically, for polyolefin (polyethylene and polypropylene) characterization. Polymer Char's technology is present in the petrochemical and research and development industries in over 20 countries in North America, South America, Europe, Africa, and Asia.
=== Platelet derived growth factor === The majority of the substrates of platelet-derived growth factor (PDGF) exhibit similar structures to Src Homology 2 domain. These substrates will bind to the PDGFR receptors which will dimerize and autophosphorylate. This phosphorylation attracted PLC-gamma (induces cell proliferation), Ras (which goes through signaling cascade and acts as a transcription factor), phosphatidylinositol 3-kinase (PI3K) which also promotes a signaling cascade inducing transcription factors, and stress fiber formation, and induces the STAT pathway which activates transcription factors.
Sources: en.wikipedia.org
=== Metabolism === CoQ10 is metabolized in all tissues, with the metabolites phosphorylated in cells. CoQ10 is reduced to ubiquinol during or after absorption in the small intestine. It is absorbed by chylomicrons, and redistributed in the blood within lipoproteins. Its elimination occurs via biliary and fecal excretion.
== External links == N-Terminal Fusion of Target Protein to Maltose-Binding Protein at Michigan Technological University maltose-binding+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Generic protocol for the expression and purification of recombinant proteins in Escherichia coli using a combinatorial His6-maltose binding protein fusion tag
=== Men's physique === Due to those who found open-bodybuilding to be "too big" or "ugly" and unhealthy, a new category was started in 2013. The first Men's Physique Olympia winner was Mark Wingson, who was followed by Jeremy Buendia for four consecutive years. Like open-bodybuilding, the federations in which bodybuilders can compete are natural divisions as well as normal ones. The main difference between the two is that men's physique competitors pose in board shorts rather than a traditional posing suit and open-bodybuilders are much larger and are more muscular than the men's physique competitors. Open-bodybuilders have an extensive routine for posing while the Physique category is primarily judged by the front and back poses. Many of the men's physique competitors are not above 200 lbs and have a bit of a more attainable and aesthetic physique in comparison to open-bodybuilders. Although this category started off slowly, it has grown tremendously, and currently men's physique seems to be a more popular class than open-bodybuilding.
Sources: en.wikipedia.org
=== Endocrine === Dexamethasone is the treatment for the very rare disorder of glucocorticoid resistance. In adrenal insufficiency and Addison's disease, dexamethasone is prescribed when the patient does not respond well to prednisone or methylprednisolone. It can be used in congenital adrenal hyperplasia in older adolescents and adults to suppress adrenocorticotropic hormone (ACTH) production. It is typically given at night.
It is worth mentioning that the pharmacokinetics of quisqualic acid has not been extensively studied and there is sparse information available on its ADME process. Therefore, more research is needed to fully understand the metabolism of the acid in the body.
Algae also use chlorophyll, but various other pigments are present, such as phycocyanin, carotenes, and xanthophylls in green algae, phycoerythrin in red algae (rhodophytes) and fucoxanthin in brown algae and diatoms resulting in a wide variety of colors. These pigments are embedded in plants and algae in complexes called antenna proteins. In such proteins, the pigments are arranged to work together. Such a combination of proteins is also called a light-harvesting complex. Although all cells in the green parts of a plant have chloroplasts, the majority of those are found in specially adapted structures called leaves. Certain species adapted to conditions of strong sunlight and aridity, such as many Euphorbia and cactus species, have their main photosynthetic organs in their stems. The cells in the interior tissues of a leaf, called the mesophyll, can contain between 450,000 and 800,000 chloroplasts for every square millimeter of leaf. The surface of the leaf is coated with a water-resistant waxy cuticle that protects the leaf from excessive evaporation of water and decreases the absorption of ultraviolet or blue light to minimize heating. The transparent epidermis layer allows light to pass through to the palisade mesophyll cells where most of the photosynthesis takes place.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.